This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1991 Feb;2(2):93-106.

doi: 10.1093/oxfordjournals.annonc.a057892.

The influence of information on drug resistance on protocol design

V T DeVita Jr¹

Affiliations

PMID: 2054322
DOI: 10.1093/oxfordjournals.annonc.a057892

Free article

Review

The influence of information on drug resistance on protocol design

V T DeVita Jr. Ann Oncol. 1991 Feb.

Free article

. 1991 Feb;2(2):93-106.

doi: 10.1093/oxfordjournals.annonc.a057892.

Author

V T DeVita Jr¹

Affiliation

¹ Memorial Sloan-Kettering Cancer Center, New York, N.Y.

PMID: 2054322
DOI: 10.1093/oxfordjournals.annonc.a057892

No abstract available

PubMed Disclaimer

Similar articles

Dose intensity. The neglected variable in clinical trials.
Surbone A, DeVita VT Jr. Surbone A, et al. Ann N Y Acad Sci. 1993 Nov 30;698:279-88. doi: 10.1111/j.1749-6632.1993.tb17219.x. Ann N Y Acad Sci. 1993. PMID: 8279768 No abstract available.
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Becher R, Kurschel E, Wandl U, Kloke O, Scheulen M, Weinhardt O, Höffken K, Niederle N, Khan H, Bergner S, et al. Becher R, et al. Adv Exp Med Biol. 1988;244:225-32. doi: 10.1007/978-1-4684-5607-3_24. Adv Exp Med Biol. 1988. PMID: 3073657 Clinical Trial. No abstract available.
Eligibility and extrapolation in cancer clinical trials.
Begg CB, Engstrom PF. Begg CB, et al. J Clin Oncol. 1987 Jun;5(6):962-8. doi: 10.1200/JCO.1987.5.6.962. J Clin Oncol. 1987. PMID: 3585451 No abstract available.
[Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K. Tamura K. Rinsho Ketsueki. 2009 Apr;50(4):276-81. Rinsho Ketsueki. 2009. PMID: 19404020 Review. Japanese. No abstract available.
Adjuvant therapy in primary breast cancer.
Wolmark N, Fisher B. Wolmark N, et al. Surg Clin North Am. 1985 Feb;65(1):161-80. doi: 10.1016/s0039-6109(16)43540-1. Surg Clin North Am. 1985. PMID: 3887616 Review.

See all similar articles

Cited by

Drug resistance in oncology: from concepts to applications.
Cazin JL, Gosselin P, Cappelaere P, Robert J, Demaille A. Cazin JL, et al. J Cancer Res Clin Oncol. 1992;119(2):76-86. doi: 10.1007/BF01209660. J Cancer Res Clin Oncol. 1992. PMID: 1429830 Free PMC article. Review.
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Jensen PB, Roed H, Sehested M, Demant EJ, Vindeløv L, Christensen IJ, Hansen HH. Jensen PB, et al. Cancer Chemother Pharmacol. 1992;31(1):46-52. doi: 10.1007/BF00695993. Cancer Chemother Pharmacol. 1992. PMID: 1360876
The use of colony-stimulating factors as bone marrow support for systemic anticancer chemotherapy.
Reed E. Reed E. J Natl Med Assoc. 1994 Jun;86(6):459-64. J Natl Med Assoc. 1994. PMID: 7521398 Free PMC article. Review.
Targeted radionuclide therapy.
Ersahin D, Doddamane I, Cheng D. Ersahin D, et al. Cancers (Basel). 2011 Oct 11;3(4):3838-55. doi: 10.3390/cancers3043838. Cancers (Basel). 2011. PMID: 24213114 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database